{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T14:42:54Z","timestamp":1709217774606},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.antiviral.2004.09.003","type":"journal-article","created":{"date-parts":[[2004,11,12]],"date-time":"2004-11-12T17:23:03Z","timestamp":1100280183000},"page":"13-22","source":"Crossref","is-referenced-by-count":12,"title":["Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease"],"prefix":"10.1016","volume":"65","author":[{"given":"Christopher N.","family":"Mayhew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Sumpter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Inayat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Cibull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard L.","family":"Elford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent S.","family":"Gallicchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2\/3","key":"10.1016\/j.antiviral.2004.09.003_bib1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0163-7258(00)00050-4","article-title":"Effect of antimetabolite drugs of nucleotide metabolism on the anti-human immunodeficiency virus activity of nucleoside reverse transcriptase inhibitors","volume":"87","author":"Balzarini","year":"2000","journal-title":"Pharmacol. Ther."},{"issue":"32","key":"10.1016\/j.antiviral.2004.09.003_bib2","doi-asserted-by":"crossref","first-page":"21509","DOI":"10.1016\/S0021-9258(18)54668-8","article-title":"Mechanism of the potentiating effect of ribavirin on the activity of 2\u2032,3\u2032-dideoxyinosine against human immunodeficiency virus","volume":"266","author":"Balzarini","year":"1991","journal-title":"J. Biol. Chem."},{"issue":"34","key":"10.1016\/j.antiviral.2004.09.003_bib3","doi-asserted-by":"crossref","first-page":"16037","DOI":"10.1016\/S0021-9258(18)66672-4","article-title":"Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis","volume":"261","author":"Bianchi","year":"1986","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.antiviral.2004.09.003_bib4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00042560-200012010-00006","article-title":"Long-term safety and antiretroviral activity of hydroxyurea and didanosine in HIV-infected patients","volume":"25","author":"Biron","year":"2000","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"1","key":"10.1016\/j.antiviral.2004.09.003_bib5","first-page":"36","article-title":"Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management","volume":"5","author":"Boelaert","year":"1996","journal-title":"Infect. Agents Dis."},{"key":"10.1016\/j.antiviral.2004.09.003_bib6","first-page":"A58","article-title":"Novel ribonucleotide reductase (RR) inhibitors, didox and trimidox, produce antiretroviral effects in the murine acquired immunodeficiency (MAIDS) and in the HIV-infected HuPBMC SCID models","volume":"37","author":"Broud","year":"1998","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.antiviral.2004.09.003_bib7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1128\/JVI.61.2.383-387.1987","article-title":"Abrogation of resistance to severe mousepox in C57BL6 mice infected with LP-BM5 murine leukemia viruses","volume":"61","author":"Buller","year":"1987","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.antiviral.2004.09.003_bib8","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1128\/JVI.65.8.4232-4241.1991","article-title":"Characteristics and contributions of defective, ecotropic, and mink cell focus-inducing viruses involved in a retrovirus-induced immunodeficiency syndrome of mice","volume":"65","author":"Chattopadhyay","year":"1991","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2004.09.003_bib9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/infdis\/171.3.521","article-title":"Reducing T cell activation as a therapy for human immunodeficiency virus infection","volume":"171","author":"Corey","year":"1995","journal-title":"J. Infect. Dis."},{"issue":"1372","key":"10.1016\/j.antiviral.2004.09.003_bib10","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1098\/rspb.1996.0133","article-title":"Anti-CD4 therapy for AIDS suggested by mathematical models","volume":"263","author":"De Boer","year":"1996","journal-title":"Proc. R. Soc. Lond. B. Biol. Sci."},{"issue":"3","key":"10.1016\/j.antiviral.2004.09.003_bib11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00002030-199902250-00010","article-title":"Bone marrow macrophage iron grade and survival of HIV-seropositive patients","volume":"13","author":"de Monye","year":"1999","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.antiviral.2004.09.003_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/intimm\/7.1.131","article-title":"Modulation of specific T cell responses by concurrent infection with Leishmania major and LP-BM5 murine leukemia viruses","volume":"7","author":"Doherty","year":"1995","journal-title":"Int. Immunol."},{"issue":"2","key":"10.1016\/j.antiviral.2004.09.003_bib13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0163-7258(85)90031-2","article-title":"Inhibition of nucleoside diphosphate reductase by hydroxybenzohydroxamic acid derivatives","volume":"29","author":"Elford","year":"1985","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2004.09.003_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0065-2571(81)90014-5","article-title":"Regulation of ribonucleotide reductase in mammalian cells by chemotherapeutic agents","volume":"19","author":"Elford","year":"1980","journal-title":"Adv. Enzyme Regul."},{"issue":"3","key":"10.1016\/j.antiviral.2004.09.003_bib15","first-page":"844","article-title":"New ribonucleotide reductase inhibitors with antineoplastic activity","volume":"39","author":"Elford","year":"1979","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.antiviral.2004.09.003_bib16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1006\/viro.2002.1649","article-title":"Repeated cycles of alternate administration of fludarabine and zidovudine plus didanosine inhibits murine AIDS and reduces proviral DNA content in lymph nodes to undetectable levels","volume":"302","author":"Fraternale","year":"2002","journal-title":"Virology"},{"issue":"7","key":"10.1016\/j.antiviral.2004.09.003_bib17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0024-3205(98)00305-1","article-title":"Enhanced effects of adriamycin by combination with a new ribonucleotide reductase inhibitor, trimidox, in murine leukemia","volume":"63","author":"Fritzer-Szekeres","year":"1998","journal-title":"Life Sci."},{"issue":"18","key":"10.1016\/j.antiviral.2004.09.003_bib18","doi-asserted-by":"crossref","first-page":"8333","DOI":"10.1073\/pnas.92.18.8333","article-title":"Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2\u2032,3\u2032-dideoxynucleoside activities against replication of human immunodeficiency virus","volume":"92","author":"Gao","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.antiviral.2004.09.003_bib19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/0006-2952(95)00106-A","article-title":"Enhancement by hydroxyurea of the anti-human immunodeficiency virus type 1 potency of 2\u2032-beta-fluoro-2\u2032,3\u2032-dideoxyadenosine in peripheral blood mononuclear cells","volume":"50","author":"Gao","year":"1995","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.antiviral.2004.09.003_bib20","first-page":"767","article-title":"Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2\u2032,3\u2032-dideoxynucleosides","volume":"46","author":"Gao","year":"1994","journal-title":"Mol. Pharmacol."},{"issue":"11","key":"10.1016\/j.antiviral.2004.09.003_bib21","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1097\/00002030-200107270-00007","article-title":"ACTG 5025 Study Group. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression","volume":"15","author":"Havlir","year":"2001","journal-title":"AIDS"},{"issue":"12","key":"10.1016\/j.antiviral.2004.09.003_bib22","doi-asserted-by":"crossref","first-page":"6562","DOI":"10.1128\/JVI.65.12.6562-6571.1991","article-title":"The majority of cells infected with the defective murine AIDS virus belong to the B-cell lineage","volume":"65","author":"Huang","year":"1991","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.antiviral.2004.09.003_bib23","first-page":"1551","article-title":"Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus","volume":"55","author":"Johns","year":"1998","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"10.1016\/j.antiviral.2004.09.003_bib24","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1096\/fasebj.5.10.2065888","article-title":"Murine acquired immunodeficiency syndrome (MAIDS): an animal model to study the AIDS pathogenesis","volume":"5","author":"Jolicoeur","year":"1991","journal-title":"FASEB J."},{"issue":"10","key":"10.1016\/j.antiviral.2004.09.003_bib25","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1128\/JVI.68.10.6767-6769.1994","article-title":"In murine AIDS, B cells are early targets of defective virus and are required for efficient infection and expression of defective virus in T cells and macrophages","volume":"68","author":"Kim","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2004.09.003_bib26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/09553006214550911","article-title":"Experiment and discussion on leukaemogenesis induced cell free extracts of radiation-induced leukaemia in mice","volume":"5","author":"Laterjet","year":"1962","journal-title":"Int. J. Radiat. Biol."},{"issue":"12","key":"10.1016\/j.antiviral.2004.09.003_bib27","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/00002030-199908200-00001","article-title":"Hydroxyurea and HIV: 5 years later\u2014from antiviral to immune-modulating effects","volume":"13","author":"Lori","year":"1999","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.antiviral.2004.09.003_bib28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1089\/088922299310917","article-title":"Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir)","volume":"15","author":"Lori","year":"1999","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"15","key":"10.1016\/j.antiviral.2004.09.003_bib29","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1089\/088922299310034","article-title":"Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters","volume":"15","author":"Lori","year":"1999","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"Suppl. 4","key":"10.1016\/j.antiviral.2004.09.003_bib30","first-page":"25","article-title":"Hydroxyurea: mechanisms of HIV-1 inhibition","volume":"3","author":"Lori","year":"1998","journal-title":"Antivir. Ther."},{"issue":"5186","key":"10.1016\/j.antiviral.2004.09.003_bib31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.7973634","article-title":"Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication","volume":"266","author":"Lori","year":"1994","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.antiviral.2004.09.003_bib32","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1089\/aid.1997.13.1093","article-title":"Antiretroviral effect of combined zidovudine and reduced glutathione therapy in murine AIDS","volume":"13","author":"Magnani","year":"1997","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"3","key":"10.1016\/j.antiviral.2004.09.003_bib33","first-page":"181","article-title":"Hydroxyurea in the treatment of HIV-1 infection: toxicity and side effects","volume":"13","author":"Maserati","year":"1999","journal-title":"J. Biol. Regul. Homeost. Agents"},{"issue":"5","key":"10.1016\/j.antiviral.2004.09.003_bib34","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/095632020201300506","article-title":"Short-term treatment with novel ribonucleotide reductase inhibitors trimidox and didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea","volume":"13","author":"Mayhew","year":"2002","journal-title":"Antivir. Chem. Chemother."},{"issue":"2","key":"10.1016\/j.antiviral.2004.09.003_bib35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0166-3542(02)00108-0","article-title":"Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox; novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea","volume":"56","author":"Mayhew","year":"2002","journal-title":"Antivir. Res."},{"issue":"6","key":"10.1016\/j.antiviral.2004.09.003_bib36","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/stem.170345","article-title":"In vivo and in vitro comparison of the short-term hematopoietic toxicity \\ hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential HIV-1 activity","volume":"17","author":"Mayhew","year":"1999","journal-title":"Stem Cells"},{"issue":"7","key":"10.1016\/j.antiviral.2004.09.003_bib37","first-page":"1019","article-title":"Effective use of ribonucleotide reductase inhibitors (didox and trimidox) alone or in combination with didanosine (ddI) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS)","volume":"43","author":"Mayhew","year":"1997","journal-title":"Cell. Mol. Biol. (Noisy-le-grand)"},{"issue":"7","key":"10.1016\/j.antiviral.2004.09.003_bib38","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00002030-199207000-00001","article-title":"Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS","volume":"6","author":"Morse","year":"1992","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.antiviral.2004.09.003_bib39","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0891-5849(95)00047-2","article-title":"The role of oxidative stress in HIV disease","volume":"19","author":"Pace","year":"1995","journal-title":"Free Radic. Biol. Med."},{"issue":"8","key":"10.1016\/j.antiviral.2004.09.003_bib40","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1128\/AAC.43.8.2046","article-title":"Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates","volume":"43","author":"Palmer","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5A","key":"10.1016\/j.antiviral.2004.09.003_bib41","first-page":"3437","article-title":"DNA-protective activity of new ribonucleotide reductase inhibitors","volume":"17","author":"Rauko","year":"1997","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.antiviral.2004.09.003_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1310\/BUPX-53L0-JEY4-FF1L","article-title":"Combination therapy with hydroxyurea versus without hydroxyurea as first line treatment options for antiretroviral-na\u00efve patients","volume":"1","author":"Rodriguez","year":"2000","journal-title":"HIV Clin. Trials."},{"issue":"14","key":"10.1016\/j.antiviral.2004.09.003_bib43","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1097\/00002030-200009290-00011","article-title":"Long-term hydroxyurea in combination with didanosine and stuvadine for the treatment of HIV-1 infection. Swiss Cohort Study","volume":"14","author":"Rutschmann","year":"2000","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.antiviral.2004.09.003_bib44","doi-asserted-by":"crossref","first-page":"F71","DOI":"10.1097\/00002030-199808000-00003","article-title":"A placebo controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study","volume":"12","author":"Rutschmann","year":"1998","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.antiviral.2004.09.003_bib45","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1128\/JVI.65.5.2290-2298.1991","article-title":"Deoxyadenosine reverses hydroxyurea inhibition of vaccinia virus growth","volume":"65","author":"Slabaugh","year":"1991","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.antiviral.2004.09.003_bib46","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/0006-2952(84)90421-0","article-title":"Deoxyribonucleoside triphosphate pools in human diploid fibroblasts and their modulation by hydroxyurea and deoxynucleosides. Does hydroxyurea inhibit DNA replication in mouse cells by more than one mechanism?","volume":"33","author":"Snyder","year":"1984","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.antiviral.2004.09.003_bib47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.antiviral.2003.11.007","article-title":"In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: Suppression of retrovirus-induced immunodeficiency disease","volume":"62","author":"Sumpter","year":"2004","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.antiviral.2004.09.003_bib48","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00042560-199808010-00002","article-title":"Prevention of murine AIDS development by (R)-9-(2-phosphonylmethoxypropyl) adenine","volume":"18","author":"Suruga","year":"1998","journal-title":"J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol."},{"issue":"11","key":"10.1016\/j.antiviral.2004.09.003_bib49","first-page":"785","article-title":"Iron binding capacity of trimidox (3,4,5-trihydroxybenzamidoxime), a new inhibitor of the enzyme ribonucleotide reductase","volume":"33","author":"Szekeres","year":"1995","journal-title":"Eur. J. Clin. Chem. Clin. Biochem."},{"issue":"1","key":"10.1016\/j.antiviral.2004.09.003_bib50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF00686113","article-title":"Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase","volume":"34","author":"Szekeres","year":"1994","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.antiviral.2004.09.003_bib51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev.bi.48.070179.001025","article-title":"Reduction of ribonucleotides","volume":"48","author":"Thelander","year":"1979","journal-title":"Annu. Rev. Biochem."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2004.09.003_bib52","first-page":"12","article-title":"Didox, a novel ribonucleotide reductase inhibitor, is more active than hydroxyurea in HIV-infected HuPBMC SCID mice","volume":"4","author":"Ussery","year":"1999","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2004.09.003_bib53","unstructured":"Ussery, M.A., Kunder, S.C., Zhang, H., Goldberg, G., Broud, D.D., Hall, B.E., Bacho, M., Papermaster, S., Elford, H.L., Black, P.L., 1997. The ribonucleotide reductase inhibitors hydroxyurea, didox and trimidox inhibit retroviral replication in the HIV-infected HuPBMC SCID model and the Rausher murine leukemia virus (RmuLV) model. In: Proceedings of the Fourth Conference of Retrovirsus and Opportun. Infections (abstract no. 150)."},{"key":"10.1016\/j.antiviral.2004.09.003_bib54","unstructured":"Ussery, M.A., Kunder, S.C., Goldberg, G., Broud, D.D., Hall, B.E., Bacho, M., Papermaster, S., Elford, H.L., Black, P.L., 1996. In vitro antiretroviral activity of ribonucleotide reductase inhibitors hydroxyurea, didox and trimidox in the HIV-infected HuPBMC SCID model and the Rausher murine leukemia virus (RmuLV) model: mono-and combination therapy. In: Program. Abstract of Interscience Conference on Antimicrobial Agents Chemotherapy (abstract no. I12)."},{"issue":"5","key":"10.1016\/j.antiviral.2004.09.003_bib55","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1021\/jm00191a027","article-title":"Synthesis of hydroxy- and aminosubstituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity","volume":"22","author":"van\u2019t Riet","year":"1979","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.antiviral.2004.09.003_bib56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/j.1552-4604.1996.tb04176.x","article-title":"Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I","volume":"36","author":"Villani","year":"1996","journal-title":"J. Clin. Pharmacol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354204002050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354204002050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T07:45:13Z","timestamp":1624866313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354204002050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0166354204002050"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2004.09.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}